Nectar Lifesciences Limited (NECLIFE) — Board Meeting | 14 August 2026

14 August 2026 · NSE 🟡 Notable Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Board approved Q1 FY26 results and appointed Dr. Suri as additional director.

🔄 What Changed

Net loss widened to ₹1,539.77 crores from prior quarter; EPS turned negative at ₹(0.79).

🔮 What's Next

AGM scheduled for September 18, 2026; record date September 11, 2026.

💡 Investor Takeaway

The company reported a significant net loss and negative EPS for the quarter, indicating ongoing financial challenges.

Nectar Lifesciences announced board approval of unaudited Q1 FY26 results showing consolidated revenue of ₹336.20 crores, net loss of ₹1,539.77 crores, and EPS of ₹(0.79). The board appointed Dr. Gunmala Suri as additional director effective August 15, 2026, and set the AGM for September 18, 2026, with record date September 11, 2026. Committee reconstitutions were also approved.

📄 View Original Announcement (PDF)

📊 Stock Analysis — NECLIFE ✨ Ask AI About This

About Nectar Lifesciences Limited (NECLIFE)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹208.05 CrROE: -42.1%ROCE: -13.1%

View full NECLIFE stock details →

📡 Get AI alerts when NECLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track NECLIFE — Free

💡 Ask AI about this filing

"How does the Q1 net loss compare to previous quarters?""What is the expected timeline for AGM voting on Dr. Suri's appointment?""How will the new director impact strategic direction?"

Ask AI Free →

📊 More NECLIFE filings

Announcement — 24 September 2026Nectar Lifesciences announced that its trading window closes on October 1, 2026, and remains shut un...
🟡 Board Meeting — 19 September 2026Nectar Lifesciences held its 31st AGM on September 18, 2026, approving the 2025-26 standalone financ...
🟡 Voting Results — 18 September 2026Nectar Lifesciences shareholders approved all five AGM resolutions, including adoption of FY2026 sta...
🟡 Board Meeting — 18 September 2026At the 31st AGM on September 18, 2026, Nectar Lifesciences adopted FY2025-26 standalone and consolid...
🔴 Annual Report — 22 August 2026Nectar Lifesciences announced the 2025-26 Annual Report and upcoming AGM on September 18, 2026, acce...

See all NECLIFE filings →

🔥 Also filed on 14 August 2026

CEIGALLCeigall India LimitedFinancial Results MAHAPEXLTDMaha Rashtra Apex Corporation LimitedCorporate Action SAATVIKGLSaatvik Green Energy LimitedFinancial Results LIBASLibas Consumer Products LimitedCorporate Action GENUSPOWERGenus Power Infrastructures LimitedFinancial Results LUXINDLux Industries LimitedFinancial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when NECLIFE files new disclosures

Track NECLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.